Cargando…
Evaluation of minocycline combined with favipiravir therapy in coronavirus disease 2019 patients: A case-series study
The aim of this study was to investigate the efficacy and safety of minocycline (MIN) and favipiravir combination therapy in patients with coronavirus disease 2019 (COVID-19) admitted to our hospital in Fukui Prefecture, Japan, in March and April of 2020. In this retrospective study, a favipiravir m...
Autores principales: | Itoh, Kazuhiro, Sakamaki, Ippei, Hirota, Tomoya, Iwasaki, Hiromichi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8486618/ https://www.ncbi.nlm.nih.gov/pubmed/34627706 http://dx.doi.org/10.1016/j.jiac.2021.09.016 |
Ejemplares similares
-
Frequency and Risk Factors for Persistent and Concomitant Symptoms after Hospital Discharge for Coronavirus Disease 2019 in the Pre-omicron Period: An Exploratory Longitudinal Study
por: Kobuchi, Taketsune, et al.
Publicado: (2023) -
Severe coronavirus disease 2019 (COVID‐19) pneumonia patients treated successfully with a combination of lopinavir/ritonavir plus favipiravir: Case series
por: Koba, Hayato, et al.
Publicado: (2020) -
Favipiravir-induced Liver Injury in Patients with Coronavirus Disease 2019
por: Kumar, Pramod, et al.
Publicado: (2021) -
Use of Favipiravir for the Treatment of Coronavirus Disease 2019 in the Setting of Hospitel
por: Surapat, Bhitta, et al.
Publicado: (2022) -
Sitafloxacin reduces tumor necrosis factor alpha (TNFα) converting enzyme (TACE) phosphorylation and activity to inhibit TNFα release from lipopolysaccharide-stimulated THP-1 cells
por: Sakamaki, Ippei, et al.
Publicado: (2021)